Filamon @Filamon_Ltd

Filamon welcomes Professor Andrew Chang to Filamon’s Scientific Advisory Board. His appointment strengthens Filamon’s position as an Australian drug development company focused on next-generation anti-inflammatory drugs for age-related chronic inflammatory diseases. #Biotech

Filamon MD Dr Graham Kelly will present at BIONNOVA 2026 in Shanghai on Wednesday 22 April,  joining more than 200 global leaders from Pfizer, Bristol Myers Squibb, and leading Chinese pharma groups. 📍 April 22–23, 2026 | Zhangjiang Science Hall, Shanghai #Filamon #BIONNOVA

We're pleased to share the replay of CEO & Managing Director Dr Graham Kelly's, PhD presentation from today's NWR Virtual Healthcare Conference. Watch the full replay here: youtu.be/qvnCeMf4aGU?si… @NWRcomms

REMINDER | CEO Graham Kelly will present tomorrow 3:00pm AEDT ( 25 March) at the @NWRcomms Healthcare Conference. 📌 Register here: us02web.zoom.us/webinar/regist… Questions can be submitted live or in advance via [email protected]. More info: nwrcommunications.com/events/healthc…

CEO Graham Kelly will present at 3:00pm AEDT on 25 March 2026 at the @NWRcomms Healthcare Conference. 📌 Register here: us02web.zoom.us/webinar/regist… Questions can be submitted live or in advance via [email protected]. More info: nwrcommunications.com/events/healthc…

Co-Founder & CEO, Dr Graham Kelly, will present today at @AusBiotech Invest 2025 in Melbourne, providing an update on our next-gen anti-inflammatory drugs for cancer, eye diseases & dementia advancing through clinical and preclinical studies. Register: ausbiotechic.com

Filamon CEO Dr Graham Kelly will present at the Spark + F1 Aussie Equities Day in Singapore. Filamon is developing next-gen oral anti-inflammatory drugs for cancer, eye and neurodegenerative diseases. 📅 Register: events.sparkplus.org/australian-equ… @Spark_Plus

Filamon features on @StockheadAU's Health Kick Podcast: Professor Paul de Souza joins Tim Boreham to discuss our mission to tackle #cancer and chronic disease with next-gen anti-inflammatory drugs. 🎧 Listen now: stockhead.com.au/health/health-… #Biotech

We’ve unveiled a novel oral immune checkpoint inhibitor developed with the @UNSW with dual chemo & immunotherapy effects -PD-1 downregulation, T-cell reactivation & cancer cell cytotoxicity. Now in preclinical testing. Backed by $1.6M in Fed Govt grants. filamon.com/wp-content/upl…

We’ve achieved a preclinical milestone with BETA-TT8. The oral drug reached high, sustained levels in the eye and brain, overcoming barriers that block most drugs and supporting more patient-friendly treatments for wet AMD and other serious conditions. filamon.com/wp-content/upl…

May is Macula Month – a reminder that AMD is the leading cause of blindness in over 60s. Filamon is developing BETA-002, a potential eyedrop/oral treatment for wet AMD designed to improve outcomes and patient experience. Learn more about Macula Month: mdfoundation.com.au/news/may-is-ma…

Our CEO Dr Graham Kelly, PhD, joins JustStocks to discuss the upcoming ADVICE clinical trial, which will evaluate kesonotide in patients with advanced solid cancers that are resistant to, or unsuitable for, standard treatment. 🎥 Watch the interview here: youtube.com/watch?v=I14i3z…

In this follow-up interview with @JustStocks_Au, Dr. Graham Kelly, CEO & Co-Founder of Filamon, discusses the company’s promising new treatment for wet age-related macular degeneration (AMD) a leading cause of blindness among the elderly. 🎬 Watch here: youtu.be/BipGL37WkiM?si…

CEO Dr. Graham Kelly sat down with @JustStocks to discuss @Filamon_Ltd's #dementia drug candidate, ALPHA-3 which aims to halt disease progression post-diagnosis. Watch now. 🎥youtu.be/HDhO7YaE_fI?si…

We are pleased to share the replay of Co-Founder, CEO, and MD Dr. Graham Kelly’s presentation from the NWR Virtual Healthcare Conference. 🎬 Watch the full presentation here: youtu.be/byS-MoJH9k0?si… Learn more about Filamon’s at filamon.com @NWRcomms

REMINDER | Join CEO and founder Dr Graham Kelly tomorrow (19 March) at 3:00 PM AEDT as he presents at the @NWRcomms Virtual #Healthcare Conference. 📍 Register to attend live: us02web.zoom.us/webinar/regist… 🔗 More info: nwrcommunications.com/healthconf #biotech

Join CEO & Founder Dr Graham Kelly as he presents at the @NWRcomms Virtual Healthcare Conference on Wednesday, 19 March 2025, at 3:00 PM AEDT. 📍 Register to attend live: us02web.zoom.us/webinar/regist… 🔗 More info: nwrcommunications.com/healthconf

🧠 Brain Awareness Week reminds us of the urgent need for innovation in neurodegenerative disease treatment. At Filamon, we’re developing multi-modal anti-inflammatory drugs to protect brain cells and prevent key drivers of neurodegeneration. 🔗 More: brainfoundation.org.au/brain-awarenes…

We've developed BETA-002, a first-in-class, non-injectable treatment for wet AMD & DMO designed for self-administration & broader disease action than current therapies. Now in preclinical studies, it aims to offer safer, more effective treatment options. filamon.com/wp-content/upl…

We've developed ALPHA-003, a world-first drug designed to protect brain cells by stabilising tau, TDP-43 & NfL, preventing inflammatory-driven damage in dementia. Now in preclinical studies. Read more in our February newsletter: 🔗filamon.com/wp-content/upl…